SicotteNLLivaSMKlutchRet al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol2002; 52(4): 421–428.
2.
VoskuhlRRWangHWuTCet al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: A randomised, placebo-controlled, phase 2 trial. Lancet Neurol2016; 15: 35–46.
3.
PozzilliCDe GiglioLBarlettaVTet al. Oral contraceptives combined with interferon β in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2015; 2(4): e120.
4.
SicotteNLGiesserBSTandonVet al. Testosterone treatment in multiple sclerosis: A pilot study. Arch Neurol2007; 64(5): 683–688.
5.
YagerJDDavidsonNE.Estrogen carcinogenesis in breast cancer. N Engl J Med2006; 354: 270–282.
6.
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet1996; 347: 1713–1727.
7.
MorchLSSkovlundCWHannafordPCet al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med2017; 377: 2228–2239.
8.
SjogrenLLMorchLSLøkkegaardEet al. Hormone replacement therapy and the risk of endometrial cancer: A systematic review. Maturitas2016; 91: 25–35.
9.
WeiderpassEBaronJAAdamiHOet al. Low-potency oestrogen and risk of endometrial cancer: A case-control study. Lancet1999; 353(9167): 1824–1828.
10.
MohammedKAbu DabrhAMBenkhadraKet al. Oral vs transdermal estrogen therapy and vascular events: A systematic review and meta-analysis. J Clin Endocrinol Metab2015; 100(11): 4012–4020.
11.
DillerMSchülerSBuchholzSet al. Effects of estriol on growth, gene expression and estrogen response element activation in human breast cancer cell lines. Maturitas2014; 77: 336–343.
